Company news

Viridian Therapeutics, Inc. news in 2026

Viridian Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

November 9, 2026

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

November 6, 2026

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

November 4, 2026

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

October 20, 2026

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

August 6, 2026

Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)

July 16, 2026

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa(TM) (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

June 26, 2026

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

June 26, 2026

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 6, 2026

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 5, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

May 5, 2026

Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

March 31, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL?1 Clinical Trial in Active Thyroid Eye Disease

March 30, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

March 29, 2026

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

March 19, 2026

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2026

Viridian Therapeutics Prepares for Transformational 2026

January 6, 2026

Calls in 2026

Decks in 2026